Edition:
India

Onxeo SA (C4X.PA)

C4X.PA on Paris Stock Exchange

1.28EUR
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
€1.28
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
149,260
52-wk High
€5.09
52-wk Low
€0.98

Chart for

About

Onxeo SA, formerly Bioalliance Pharma SA, is a France-based biopharmaceutical company. In July 2014, the Company, as the continuing entity, merged with Topotarget AS creating Onxeo, a company dedicated to orphan oncology diseases. Onxeo aims at holding a portfolio of advanced programs targeting severe pathologies with unmet... (more)

Overall

Beta: 0.73
Market Cap(Mil.): €88.20
Shares Outstanding(Mil.): 50.69
Dividend: --
Yield (%): --

Financials

  C4X.PA Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -0.45 -- --
ROI: -20.47 14.84 14.38
ROE: -24.16 16.34 16.07

BRIEF-Onxeo Announces Start Of DRIIV Phase 1 Clinical Study Of AsiDNA

* ANNOUNCES START OF DRIIV, PHASE 1 CLINICAL STUDY OF ASIDNA IN ADVANCED SOLID TUMORS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

24 Apr 2018

BRIEF-Onxeo FY Recurring Operating Loss Narrows To EUR 19.2‍​ Million

* FY REVENUE EUR ‍​9.5 MILLION VERSUS EUR 4.4 MILLION YEAR AGO

29 Mar 2018

BRIEF-Onxeo Presents Positive AsiDNA Preclinical Study Results

* ANNOUNCES PRESENTATION OF TWO PRECLINICAL STUDY ABSTRACTS HIGHLIGHTING ASIDNA

15 Mar 2018

BRIEF-Onxeo Says To Record Impairment Charge

* ONXEO SA SAYS IT WILL RECORD AN IMPAIRMENT CHARGE OF ABOUT EUR 38 MILLION IN ITS 2017 CONSOLIDATED ACCOUNTS

15 Mar 2018

BRIEF-Onxeo Provides Update on Litigation with SpeBio/SpePharm

* ONXEO SA - SUBMITTED CONCLUSIONS TO PARIS COURT OF APPEAL CONCERNING MERITS OF LITIGATION AGAINST SPEPHARM/SPEBIO B.V COMPANIES

24 Jan 2018

Earnings vs. Estimates